The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer

Sangeeta Rojanala, Haiyong Han, Rubén M. Muñoz, Walden Browne, Raymond B Nagle, Daniel D. Von Hoff, David J. Bearss

Research output: Contribution to journalArticle

78 Scopus citations

Abstract

Aurora-2 is a serine threonine kinase that associates with the centrosome. Overexpression or ectopic expression of Aurora-2 appears to alter centrosome number and function and has been implicated in a variety of human cancers. In this work, we demonstrate that Aurora-2 is both amplified and overexpressed in human pancreatic cancer cell lines, with a 2-5-fold increase in gene copy number and a 3-4-fold increase in protein levels compared with controls. Aurora-2 is also amplified and overexpressed in pancreatic cancers taken directly from patients. An immunohistochemistry of tissues taken directly from patients demonstrated an overexpression of Aurora-2 in 26 of 28 pancreatic cancers compared with 18 normal pancreas samples. Antisense nucleotides specifically targeted at Aurora-2 arrest the cell cycle in pancreatic cancer cells, indicating the potential of Aurora-2 as a therapeutic target in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)451-457
Number of pages7
JournalMolecular Cancer Therapeutics
Volume3
Issue number4
Publication statusPublished - Apr 2004

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Rojanala, S., Han, H., Muñoz, R. M., Browne, W., Nagle, R. B., Von Hoff, D. D., & Bearss, D. J. (2004). The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Molecular Cancer Therapeutics, 3(4), 451-457.